Endostatin in the pancreas

Wigmore, Stephen J.

doi:10.1038/sj.bjc.6602180

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 , 11 Endostatin (ES) has been found to be the strongest anti-angiogenic factor. 12 , 13 Recombinant ES has been in clinical use in some solid cancers in China. Ribonucleic acid (RNA) interference-mediated silencing of VEGF and bFGF suppresses ES secretion in pancreatic carcinoma cells.…”

Section: Introductionmentioning

confidence: 99%

Basic fibroblast growth factor shows prognostic impact on survival in operable non‐small cell lung cancer patients

Gao

et al. 2014

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThe important role of angiogenesis displaying in tumor development and metastasis has been generally realized. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and endostatin (ES) are critical members of angiogenesis modulating the balance between pro-angiogenenic and anti-angiogenenic factors. The aim of this study was to evaluate the circulating level of these factors in serum and explore their prognostic significance in 96 operable non-small cell lung cancer (NSCLC) patients.MethodsPre-operational serum VEGF, bFGF, and ES were determined by commercially available enzyme-link immunosorbent assay for 96 NSCLC patients and compared to a cohort of healthy controls (n = 51). Values were correlated with clinicopathological features and overall survival (OS).ResultsThe pretreatment serum levels of VEGF, bFGF and ES in NSCLC were significantly higher than in the healthy control (P < 0.001, P = 0.009 and P = 0.016, respectively). Univariate survival analysis showed that a high bFGF level correlated with shorter OS and remained an independent factor in multivariate analysis (hazard ratio [HR] = 1.918, 95% confidence interval [CI], 1.061–3.464). In the squamous subtype, a high bFGF indicated a particularly poor prognosis (HR = 2.609, 95% CI, 1.188–5.729).ConclusionsbFGF is an independent predictor of poor survival in patients with NSCLC. For patients with high serum bFGF, aggressive antitumor treatments should be given after surgery. Approaches targeting the bFGF signaling pathway should be considered as potentially promising therapeutic strategies in NSCLC, especially for the squamous subtype.

show abstract

Section: Introductionmentioning

confidence: 99%

Basic fibroblast growth factor shows prognostic impact on survival in operable non‐small cell lung cancer patients

Gao

et al. 2014

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…Different angiogenic growth factors may modulate each other (3,4), particularly in cases where both pro-angiogenic and anti-angiogeneic factors are involved. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are by far the most important pro-angiogenic growth factors (5,6), while endostatin has been found to be the strongest anti-angiogenic factor (6,7). In order to further study the modulatory effects between these factors, sw1990, PCT-3 and Panc-1 pancreatic cancer cell lines were infected with VEGF or bFGF siRNA, respectively.…”

Section: Introductionmentioning

confidence: 99%

RNA interference-mediated silencing of VEGF and bFGF suppresses endostatin secretion in pancreatic carcinoma cells

et al. 2013

View full text Add to dashboard Cite

Pro-angiogenic factors [vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)] and anti-angiogenic factors (endostatin) play important roles in the progression of pancreatic cancer. The purpose of the present study was to investigate the knockdown effect by either VEGF or bFGF siRNA on the expression and secretion of endostatin in pancreatic carcinoma cells. Pancreatic carcinoma cell lines (sw1990, Panc-1 and PCT-3) were treated with VEGF and bFGF siRNA. The expression of VEGF, bFGF and endostatin in pancreatic carcinoma cell lines was determined by reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis. Secretion of endostatin was measured by enzyme-linked immunosorbent assay (ELISA). bFGF and VEGF siRNA significantly reduced the expression of bFGF and VEGF mRNA, respectively, but did not affect mRNA and protein expression of endostatin in pancreatic carcinoma cell lines. However, secretion of endostatin in PCT-3, Panc-1 and sw1990 cells was significantly inhibited by bFGF and VEGF siRNA. This study demonstrated that pro-angiogenic factors (VEGF and bFGF) differentially modulate expression and secretion of anti-angiogenic factors (endostatin). This result may have important implications in the anti-angiogenesis therapy in pancreatic cancer.

show abstract

Monoclonaux contre inhibiteurs de tyrosine kinase

Bozec

Milano

2008

Les Thérapies Ciblées

View full text Add to dashboard Cite

Endostatin in the pancreas

Cited by 3 publications

References 9 publications

Basic fibroblast growth factor shows prognostic impact on survival in operable non‐small cell lung cancer patients

Basic fibroblast growth factor shows prognostic impact on survival in operable non‐small cell lung cancer patients

RNA interference-mediated silencing of VEGF and bFGF suppresses endostatin secretion in pancreatic carcinoma cells

Monoclonaux contre inhibiteurs de tyrosine kinase

Contact Info

Product

Resources

About